{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:18:22Z","timestamp":1787969902992,"version":"build-2784847793"},"reference-count":33,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>The aim of the study was to evaluate the predictive value of postoperative day 1 (POD1) prolactin on long-term hyperprolactinemia normalization following prolactinoma resection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The authors retrospectively reviewed 260 prolactinomas that were resected from 1998 to 2020. Patients were classified on the basis of preoperative dopamine agonist (DA) use: the DA-positive group (n = 112 [43.1%]) used DAs &lt; 3 weeks prior to surgery, while the DA-negative group (n = 148 [56.9%]) did not. The prolactin level (ng\/ml) was categorized as follows: low normal (0\u201310 ng\/ml for men, 0\u201312.5 ng\/ml for women), high normal (10\u201320 ng\/ml for men, 12.5\u201325 ng\/ml for women), and mildly hyperprolactinemic (20\u201340 ng\/ml for men, 25\u201350 ng\/ml for women). Prolactins were analyzed at 6 time points: POD1, 1 day to 6 weeks, 6\u201312 weeks, 12 weeks to 6 months, 6 months to 1 year, and &gt; 1 year. The authors identified cases with POD1 normalization, followed by hyperprolactinemia requiring treatment, multiple elevated prolactins, or hyperprolactinemia at latest follow-up, defining rebound hyperprolactinemia as these events that occurred &lt; 1 year of surgery and recurrent hyperprolactinemia as these events that occurred \u2265 1 year after surgery. Remission was defined as persistent normalization during the 1st year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The mean (SD) age was 35.4 (11.4) years. In total, 78.1% (n = 203) of patients were female. In the DA-negative group, 78.9% of mildly hyperprolactinemic patients had persistent elevation, while 90.2% and 37.0% of low- and high-normal patients achieved remission, respectively. For the DA-positive group, 81.8% of mildly hyperprolactinemic DA-positive patients remained with elevated prolactin levels, whereas 72.6% and 50.0% of low- and high-normal patients experienced remission, respectively. Rebound rates were 2.0% versus 33.3% in low-normal versus high-normal DA-negative patients and 12.6% versus 33.3% in low-normal versus high-normal DA-positive patients. Recurrence rates were 7.8% versus 25.9% in low-normal versus high-normal DA-negative patients and 11.6% versus 16.7% in low-normal versus high-normal DA-positive patients. The cumulative incidence rates of rebound (p &lt; 0.001) and recurrent (p &lt; 0.001) hyperprolactinemia varied by group, with low-normal DA-negative patients being the least likely to experience either outcome. For DA-positive (p &lt; 0.001) and DA-negative (p &lt; 0.001) patients, retreatment during the 1st year after surgery was more often required in mildly hyperprolactinemic (47.4% of DA-negative patients vs 81.8% of DA-positive patients) and high-normal (18.5% DA-negative vs 33.3% DA-positive) patients than low-normal patients (1.0% DA-negative vs 18.1% DA-positive).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>POD1 prolactin is associated with long-term normalization following prolactinoma resection. However, patients should not be considered cured solely on the basis of the POD1 prolactin level, as rebound hyperprolactinemia can occur, particularly with recent DA use or a high-normal POD1 prolactin level.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2025.12.jns25730","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:51:58Z","timestamp":1778896318000},"page":"1-16","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of postoperative day 1 prolactin following prolactinoma resection"],"prefix":"10.3171","author":[{"given":"Zain","family":"Peeran","sequence":"first","affiliation":[{"name":"School of Medicine, University of California, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poojan","family":"Shukla","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tej","family":"Tummala","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymen","family":"Kabir","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Osorio","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Kourkoulakos","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary G.","family":"Brumm","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Joe","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Lui","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarav","family":"Badani","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmon S.","family":"Khela","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob S.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan H.","family":"El-Sayed","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose G.","family":"Gurrola","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Theodosopoulos","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Blevins","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kunwar","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish K.","family":"Aghi","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"5","key":"b1","series-title":"JAMA","first-page":"516","article-title":"Diagnosis and treatment of pituitary adenomas","volume":"317","author":"Molitch ME","year":"2017","unstructured":"Molitch ME. Diagnosis and treatment of pituitary adenomas. JAMA. 2017;317(5):516\u2013524. doi:10.1001\/jama.2016.19699"},{"issue":"5","key":"b2","series-title":"Am Fam Physician","first-page":"319","article-title":"Pituitary adenomas: an overview","volume":"88","author":"Lake MG","year":"2013","unstructured":"Lake MG, Krook LS, Cruz SV. Pituitary adenomas: an overview. Am Fam Physician. 2013;88(5):319\u2013327."},{"issue":"1","key":"b3","series-title":"Pituitary","first-page":"3","article-title":"The epidemiology of prolactinomas","volume":"8","author":"Ciccarelli A","year":"2005","unstructured":"Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary. 2005;8(1):3\u20136. doi:10.1007\/s11102-005-5079-0"},{"issue":"2","key":"b4","series-title":"Best Pract Res Clin Endocrinol Metab","first-page":"101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: the old and the new","volume":"33","author":"Chanson P","year":"2019","unstructured":"Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101290. doi:10.1016\/j.beem.2019.101290"},{"issue":"1","key":"b5","series-title":"Endocr Pathol","first-page":"6","article-title":"Overview of the 2022 WHO Classification of Pituitary Tumors","volume":"33","author":"Asa SL","year":"2022","unstructured":"Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol. 2022;33(1):6\u201326. doi:10.1007\/s12022-022-09703-7"},{"key":"b6","series-title":"Front Endocrinol (Lausanne)","first-page":"636","article-title":"The chance of permanent cure for micro- and macroprolactinomas, medication or surgery? A systematic review and meta-analysis","volume":"9","author":"Ma Q","year":"2018","unstructured":"Ma Q, Su J, Li Y,  The chance of permanent cure for micro- and macroprolactinomas, medication or surgery? A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2018;9:636. doi:10.3389\/fendo.2018.00636"},{"issue":"4","key":"b7","series-title":"Neurosurg Clin N Am","first-page":"669","article-title":"Medical versus surgical management of prolactinomas","volume":"23","author":"Oh MC","year":"2012","unstructured":"Oh MC, Kunwar S, Blevins L, Aghi MK. Medical versus surgical management of prolactinomas. Neurosurg Clin N Am. 2012;23(4):669\u2013678. doi:10.1016\/j.nec.2012.06.010"},{"issue":"1","key":"b8","series-title":"Neuroendocrinology","first-page":"77","article-title":"Surgery for prolactinomas to date","volume":"109","author":"Buchfelder M","year":"2019","unstructured":"Buchfelder M, Zhao Y, Schlaffer SM. Surgery for prolactinomas to date. Neuroendocrinology. 2019;109(1):77\u201381. doi:10.1159\/000497331"},{"key":"b9","series-title":"World Neurosurg","first-page":"e349","article-title":"Determinants of surgical remission in prolactinomas: a systematic review and meta-analysis","volume":"154","author":"Wright K","year":"2021","unstructured":"Wright K, Chaker L, Pacione D,  Determinants of surgical remission in prolactinomas: a systematic review and meta-analysis. World Neurosurg. 2021;154:e349\u2013e369. doi:10.1016\/j.wneu.2021.07.035"},{"issue":"6","key":"b10","series-title":"J Clin Endocrinol Metab","first-page":"e1833","article-title":"The changing treatment paradigm for prolactinoma\u2014a prospective series of 100 consecutive neurosurgical cases","volume":"110","author":"van Trigt VR","year":"2025","unstructured":"van Trigt VR, Bakker LEH, Pelsma ICM,  The changing treatment paradigm for prolactinoma\u2014a prospective series of 100 consecutive neurosurgical cases. J Clin Endocrinol Metab. 2025;110(6):e1833\u2013e1844. doi:10.1210\/clinem\/dgae652"},{"key":"b11","series-title":"Front Endocrinol (Lausanne)","first-page":"439","article-title":"Prolactinomas: prognostic factors of early remission after transsphenoidal surgery","volume":"11","author":"Zielinski G","year":"2020","unstructured":"Zielinski G, Ozdarski M, Maksymowicz M, Szamotulska K, Witek P. Prolactinomas: prognostic factors of early remission after transsphenoidal surgery. Front Endocrinol (Lausanne). 2020;11:439. doi:10.3389\/fendo.2020.00439"},{"issue":"3","key":"b12","series-title":"Brain Tumor Res Treat","first-page":"204","article-title":"Role of immediate postoperative prolactin measurement in female prolactinoma patients: predicting long-term remission after complete tumor removal","volume":"11","author":"Lee GY","year":"2023","unstructured":"Lee GY, Kim SH, Kim EH. Role of immediate postoperative prolactin measurement in female prolactinoma patients: predicting long-term remission after complete tumor removal. Brain Tumor Res Treat. 2023;11(3):204\u2013209. doi:10.14791\/btrt.2023.0023"},{"issue":"15","key":"b13","series-title":"J Korean Med Sci","first-page":"e97","article-title":"Long-term outcome of microscopic transsphenoidal surgery for prolactinomas as an alternative to dopamine agonists","volume":"36","author":"Park K","year":"2021","unstructured":"Park K, Park KH, Park HR,  Long-term outcome of microscopic transsphenoidal surgery for prolactinomas as an alternative to dopamine agonists. J Korean Med Sci. 2021;36(15):e97. doi:10.3346\/jkms.2021.36.e97"},{"issue":"1","key":"b14","series-title":"Neurosurg Rev","first-page":"128","article-title":"Surgery as first-line treatment for prolactinoma? Discussion of the literature and results of a consecutive series of surgically treated patients","volume":"46","author":"Ottenhausen M","year":"2023","unstructured":"Ottenhausen M, Conrad J, Wolters LM, Ringel F. Surgery as first-line treatment for prolactinoma? Discussion of the literature and results of a consecutive series of surgically treated patients. Neurosurg Rev. 2023;46(1):128. doi:10.1007\/s10143-023-02033-0"},{"issue":"3","key":"b15","series-title":"Eur J Endocrinol","first-page":"R89","article-title":"Therapy of endocrine disease: surgery in microprolactinomas: effectiveness and risks based on contemporary literature","volume":"175","author":"Tampourlou M","year":"2016","unstructured":"Tampourlou M, Trifanescu R, Paluzzi A, Ahmed SK, Karavitaki N. Therapy of endocrine disease: surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Eur J Endocrinol. 2016;175(3):R89\u2013R96. doi:10.1530\/EJE-16-0087"},{"issue":"2","key":"b16","series-title":"J Neurosurg","first-page":"307","article-title":"Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery","volume":"97","author":"Amar AP","year":"2002","unstructured":"Amar AP, Couldwell WT, Chen JCT, Weiss MH. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg. 2002;97(2):307\u2013314. doi:10.3171\/jns.2002.97.2.0307"},{"issue":"7","key":"b17","series-title":"Clin Pharmacokinet","first-page":"633","article-title":"Clinical pharmacokinetics of cabergoline","volume":"42","author":"Del Dotto P","year":"2003","unstructured":"Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet. 2003;42(7):633\u2013645. doi:10.2165\/00003088-200342070-00003"},{"issue":"9","key":"b18","series-title":"Paediatr Child Health","first-page":"535","article-title":"Pharmacokinetics 101","volume":"16","author":"Ito S","year":"2011","unstructured":"Ito S. Pharmacokinetics 101. Paediatr Child Health. 2011;16(9):535\u2013536. doi:10.1093\/pch\/16.9.535"},{"issue":"8","key":"b19","series-title":"Arch Med Res","first-page":"102893","article-title":"Long-term discontinuation of dopamine agonist treatment in patients with prolactinomas revisited","volume":"54","author":"Sosa-Eroza E","year":"2023","unstructured":"Sosa-Eroza E, Espinosa-C\u00e1rdenas E. Long-term discontinuation of dopamine agonist treatment in patients with prolactinomas revisited. Arch Med Res. 2023;54(8):102893. doi:10.1016\/j.arcmed.2023.102893"},{"issue":"7","key":"b20","series-title":"J Clin Endocrinol Metab","first-page":"2428","article-title":"Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy","volume":"94","author":"Kharlip J","year":"2009","unstructured":"Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab. 2009;94(7):2428\u20132436. doi:10.1210\/jc.2008-2103"},{"issue":"12","key":"b21","series-title":"Nat Rev Endocrinol","first-page":"722","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn S","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF,  Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023;19(12):722\u2013740. doi:10.1038\/s41574-023-00886-5"},{"issue":"5","key":"b22","series-title":"J Neurosurg","first-page":"990","article-title":"Defining postoperative values for successful resection of prolactinomas","volume":"85","author":"Couldwell W","year":"1996","unstructured":"Couldwell W, Weiss M. Defining postoperative values for successful resection of prolactinomas. J Neurosurg. 1996;85(5):990\u2013991. doi:10.3171\/jns.1996.85.5.0990a"},{"issue":"10","key":"b23","series-title":"J Endocr Soc","first-page":"bvab074","article-title":"Cure and hormonal control after prolactinoma resection: case series and systematic review","volume":"5","author":"Penn MC","year":"2021","unstructured":"Penn MC, Cardinal T, Zhang Y,  Cure and hormonal control after prolactinoma resection: case series and systematic review. J Endocr Soc. 2021;5(10):bvab074. doi:10.1210\/jendso\/bvab074"},{"issue":"1","key":"b24","series-title":"Endocr Pract","first-page":"70","article-title":"Effect of the preoperative use of dopamine agonists in the postoperative course of prolactinomas: a systematic review","volume":"20","author":"Carija R","year":"2014","unstructured":"Carija R, Tudor M, Vucina D. Effect of the preoperative use of dopamine agonists in the postoperative course of prolactinomas: a systematic review. Endocr Pract. 2014;20(1):70\u201374. doi:10.4158\/EP13165.RA"},{"issue":"3","key":"b25","series-title":"Pituitary","first-page":"158","article-title":"Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection","volume":"12","author":"Sughrue ME","year":"2009","unstructured":"Sughrue ME, Chang EF, Tyrell JB, Kunwar S, Wilson CB, Blevins LS. Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection. Pituitary. 2009;12(3):158\u2013164. doi:10.1007\/s11102-008-0135-1"},{"key":"b26","series-title":"Int J Endocrinol","first-page":"9930059","article-title":"Surgery and medical treatment in microprolactinoma: a systematic review and meta-analysis","volume":"2021","author":"Lu J","year":"2021","unstructured":"Lu J, Cai L, Wu Z,  Surgery and medical treatment in microprolactinoma: a systematic review and meta-analysis. Int J Endocrinol. 2021;2021:9930059\u20139930011. doi:10.1155\/2021\/9930059"},{"issue":"1","key":"b27","series-title":"Neurosurgery","first-page":"36","article-title":"Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up","volume":"50","author":"Thomson JA","year":"2002","unstructured":"Thomson JA, Gray CE, Teasdale GM. Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up. Neurosurgery. 2002;50(1):36\u201340. doi:10.1097\/00006123-200201000-00007"},{"issue":"5","key":"b28","series-title":"N Engl J Med","first-page":"280","article-title":"Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma","volume":"309","author":"Serri O","year":"1983","unstructured":"Serri O, Rasio E, Beauregard H, Hardy J, Somma M. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med. 1983;309(5):280\u2013283. doi:10.1056\/NEJM198308043090505"},{"issue":"12","key":"b29","series-title":"Cancer","first-page":"2422","article-title":"Late recurrence of surgically removed prolactinomas","volume":"57","author":"Parl FF","year":"1986","unstructured":"Parl FF, Cruz VE, Cobb CA, Bradley CA, Aleshire SL. Late recurrence of surgically removed prolactinomas. Cancer. 1986;57(12):2422\u20132426. doi:10.1002\/1097-0142(19860615)57:12<2422::AID-CNCR2820571229>3.0.CO;2-B"},{"key":"b30","series-title":"World Neurosurg","first-page":"e333","article-title":"The role of endoscopic transsphenoidal surgery in microprolactinomas: a retrospective study","volume":"191","author":"Zhu Z","year":"2024","unstructured":"Zhu Z, Li Z, Luo L,  The role of endoscopic transsphenoidal surgery in microprolactinomas: a retrospective study. World Neurosurg. 2024;191:e333\u2013e340. doi:10.1016\/j.wneu.2024.08.124"},{"key":"b31","series-title":"StatPearls","article-title":"Physiology, prolactin","author":"Al-Chalabi M","year":"2023","unstructured":"Al-Chalabi M, Bass AN, Alsalman I. Physiology, prolactin. In: StatPearls. StatPearls Publishing; 2023."},{"issue":"11","key":"b32","series-title":"J Clin Invest","first-page":"1603","article-title":"Mechanisms for pituitary tumorigenesis: the plastic pituitary","volume":"112","author":"Melmed S","year":"2003","unstructured":"Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest. 2003;112(11):1603\u20131618. doi:10.1172\/JCI20401"},{"issue":"10","key":"b33","series-title":"Metabolism","first-page":"905","article-title":"Gradual recovery of lactotroph responsiveness to dynamic stimulation following surgical removal of prolactinomas: Long-term follow-up studies","volume":"35","author":"Arafah BM","year":"1986","unstructured":"Arafah BM, Brodkey JS, Pearson OH. Gradual recovery of lactotroph responsiveness to dynamic stimulation following surgical removal of prolactinomas: Long-term follow-up studies. Metabolism. 1986;35(10):905\u2013912. doi:10.1016\/0026-0495(86)90052-1"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/aop\/article-10.3171-2025.12.JNS25730\/article-10.3171-2025.12.JNS25730.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/aop\/article-10.3171-2025.12.JNS25730\/article-10.3171-2025.12.JNS25730.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/aop\/article-10.3171-2025.12.JNS25730\/article-10.3171-2025.12.JNS25730.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:36:34Z","timestamp":1787967394000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/aop\/article-10.3171-2025.12.JNS25730\/article-10.3171-2025.12.JNS25730.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":33,"URL":"https:\/\/doi.org\/10.3171\/2025.12.jns25730","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}